Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Relevante Publikationen der AG Supportive Therapie

Gralla R, Bosnjak SM, Hontsa A, Balser C, Rizzi C, Rossi G, Borroni ME, Jordan K.A Phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy Annals of Oncology 2014, 25(7):1333-9

Jahn P, Kuss O, Schmidt H, Bauer A, Kitzmantel M, Jordan K, Krasemann S, Landenberger M.Improvement of pain related self-management for cancer patients through a modular transitional nursing intervention: a cluster randomized multicenter trial Pain. 2014,155:746-755

Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE.Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma Health and Quality of Life outcomes 2014,11;12:35-44

Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C.Kardiotoxizität onkologischer Therapien Deutsches Ärzteblatt 2014,111:161-168

Jordan K, Gralla R, Jahn F, Molassiotis A.International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice European Journal of Pharmacology 2014,722:197-202 

Feyer P, Jahn F, Jordan K. Radiation induced nausea and vomiting European Journal of Pharmacology 2014,722:165-171 

Darmani N, Jordan K, Rudd A, Warr D. Guest editors Special Volume “New vistas in the pharmacology and neurochemistry of diverse causes of nausea and vomiting” European Journal of Pharmacology 2014, Vol. 722 

Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters F, Davies FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study Journal of Supportive Care in Cancer 2014,22:417-426

De Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K. Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment Onkologie 2013,36:127-135

Feyer P, Jordan K. Radiotherapy induced nausea and vomiting, UpToDate, Version updated on 12.6.2013, www.uptodate.com

Jordan K, Jahn F, Jahn P, Behlendorf  T, Stein A, Ruessel J, Kegel T, Schmoll HJ. The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination Bone Marrow Transplantation 2011,46:784-9 

Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies Annals of Oncology 2011,1:30-8

Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer PC. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 Journal of Supportive Care in Cancer 2011,19:S37-42

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art Journal of Supportive Care in Cancer 2011,19:S43-47

Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 Journal of Supportive Care in Cancer 2011,19:S5-14

Olver I, Clark-Snow RA, Ballatori E, Espersen BT, Bria E, Jordan K. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential Journal of Supportive Care in Cancer  2011,19:S33-36

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Annals of Oncology 2010, 5:v232-43

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll H.-J. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Journal of Supportive Care in Cancer 2010,18:423-31

Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting (PCNV) European Journal of Cancer Care 2010,19:603-9

Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management Therapeutic Advances in Medical Oncology 2010,2:51-63

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? The Oncologist 2009,14:1242-51 

Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy European Journal of Cancer 2009,45:1184-7

Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll, HJ, Landenberger, M. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial Journal of Supportive Care in Cancer 2009,17:1543-52

Jordan K, Müller F, Schmoll HJ. Neue antiemetische Strategien nicht nur in der Onkologie Der Internist 2009,50:887-894

Jordan K, Behlendorf T, Mueller F, Schmoll HJ. Anthracycline extravasation injuries: management with dexrazoxane Therapeutics and Clinical Risk Management 2009, 5:361-6

Jordan K, Hinke A, Grothey A, Voigt W, Arnold, D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis Journal of Supportive Care in Cancer 2007,15:1023-1033

Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Annals of Oncology 2006,17:1000-1005

Jordan K, Grothey A, Kegel T, Fibich C, Schöber C, Schmoll HJ. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting Onkologie 2005, 28:88-92

Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis Journal of Supportive Care in Cancer 2005,13:26-31

Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs Critical Review in Oncology and Hematology 2007,61:162-75

Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment European Journal of Cancer 2005,41:199-205